Algert Global LLC Acquires 21,975 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Algert Global LLC lifted its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 82.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,630 shares of the company’s stock after purchasing an additional 21,975 shares during the quarter. Algert Global LLC’s holdings in Denali Therapeutics were worth $1,417,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in DNLI. MONECO Advisors LLC boosted its position in shares of Denali Therapeutics by 4.6% during the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after acquiring an additional 400 shares in the last quarter. Assetmark Inc. boosted its position in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after acquiring an additional 580 shares in the last quarter. CWM LLC boosted its position in shares of Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after acquiring an additional 920 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Denali Therapeutics by 5.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock worth $613,000 after acquiring an additional 1,372 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. This trade represents a 50.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 86,578 shares of company stock worth $2,474,440. Company insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

DNLI has been the topic of several analyst reports. Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. Citigroup increased their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. JPMorgan Chase & Co. cut their target price on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $38.90.

Denali Therapeutics Stock Performance

Shares of NASDAQ:DNLI opened at $25.16 on Friday. The firm has a market cap of $3.62 billion, a PE ratio of -9.12 and a beta of 1.40. The firm’s fifty day moving average is $27.53 and its 200-day moving average is $24.43. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. Sell-side analysts forecast that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.